VialVIAL
Home/Compounds/ARA-290
PeptideGrey AreaClinical Trials

ARA-290

Regulatory

Legal Status in 2026

Grey Area

No formal FDA approval; occupies a regulatory grey area in 2026.

This compound occupies a regulatory grey area in 2026. It is neither explicitly FDA-approved nor clearly illegal for personal use, but it lacks formal clinical approval and may not be legally sold for human use in all contexts. Proceed with caution: source quality is variable, and regulatory status can change. Always consult a physician.

About

About ARA-290

ARA-290 is a synthetic 11-amino-acid peptide that selectively activates the innate repair receptor (a heterodimer of the EPO receptor and beta common receptor) without erythropoietic effects, providing neuroprotection, anti-inflammatory, and tissue-repair actions. It has completed Phase II trials for neuropathic pain in sarcoidosis and is being studied for small fiber neuropathy, diabetic neuropathy, and inflammatory conditions. It represents a novel approach to harnessing erythropoietin's tissue-protective properties without its blood-thickening risks.

Science

Mechanism of Action

Selectively binds the heteromeric innate repair receptor (IRR) composed of EPOR and CD131 (βcR), activating anti-apoptotic, anti-inflammatory, and regenerative intracellular pathways in neurons, immune cells, and tissue progenitor cells without stimulating erythropoiesis.

Dosing

Typical Protocol

4 mg subcutaneous injection once daily for 28 days in clinical trials; compounded versions used off-label for neuropathy.

⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.

Evidence

Evidence Tier

Clinical Trials

Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.

Availability

Provider availability

ARA-290 has no FDA approval for human use and is not available through licensed US prescribing or compounding channels, so Vial does not list providers for it.

Compound comparisons

Compare ARA-290

ARA-290 set against other compounds people weigh it against.

This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.